Thera-SAbDab

DENOSUMAB

>   Structural Summary
TherapeuticDenosumab
TargetTNFSF11
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2005
INN Year Recommended2006
Companies InvolvedAmgen, Daiichi Sankyo Company, European Thoracic Oncology Platform, GlaxoSmithKline, Jules Bordet Institute, Melbourne Health, University Health Network
Conditions ApprovedBone cancer, Bone disorders, Bone metastases, Corticosteroid-induced osteoporosis, Male osteoporosis, Malignant hypercalcaemia, Osteoporosis, Postmenopausal osteoporosis, Rheumatoid arthritis
Conditions ActiveBreast cancer, Non-small cell lung cancer, Osteogenesis imperfecta, Malignant melanoma
Conditions DiscontinuedMultiple myeloma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]